A Tonic Signaling Code Predicts CAR-T Cell Efficacy in Diffuse Midline Glioma
Deng, E. B.; Zhong, X.; Xin, D.; Soni, U. K.; Ma, W.; Huang, X.; Cai, M.; Liang, P.-Y.; Bai, J.; Qin, Q.; Mishra, S.; Hu, M.; Bayat, A. E.; Diao, J.; Xin, M.; Pillay-Smiley, N.; Hummel, T. R.; Stevenson, C. B.; Foster, J. B.; Blank, P. d.; Raskin, S.; Koschmann, C.; Cancelas, J. A.; Zheng, Y.; Lu, Q. R.
Show abstract
Diffuse midline glioma (DIPG/DMG) is a uniformly fatal pediatric brain tumor with no effective cure. Although CAR T-cell therapy shows promise, clinical outcomes remain inconsistent due to limited persistence and premature exhaustion. Reliable predictive biomarkers are lacking, and proposed exhaustion or stemness markers provide limited utility. Here, we systematically compare multiple CAR-T constructs targeting clinically-relevant antigen B7-H3 and identify antigen-independent CAR activation, or tonic signaling, as a key determinant of therapeutic performance. We find that B7-H3 CAR-T cells with restrained tonic signaling display superior tumor killing, persistence, and resistance to exhaustion, along with reduced CAR membrane clustering, in patient-derived DIPG models. Integrated multi-omics and single-cell profiling further reveal a CAR-T tonic signaling-associated gene signature that outperforms conventional exhaustion or stemness markers in predicting therapeutic efficacy across multiple clinical trials, including DIPG and other tumor types. Together, these findings define a mechanistic and predictive framework to guide CAR design and improve clinical outcomes.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma 98%
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 97%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 97%
Similar papers in this journal
- Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells 97%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- ALDH1A3-acetaldehyde metabolism potentiates transcriptionalheterogeneity in melanoma 96%
Similar papers in this journal
- PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity 97%
- An immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer 95%
- Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma 95%
Similar papers in this journal
- Cell lineage as a predictor of immune response in neuroblastoma 97%
- Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity 95%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 95%
Similar papers in this journal
- Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators 96%
- B3GALT6 Promotes Dormant Breast Cancer Cell Survival and Recurrence by Enabling Heparan Sulfate-Mediated FGF Signaling 96%
- An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.